procalcitonin
OtherThe application of antimicrobial agents is determined by PCT results.
Completed
NCT Number: NCT03058718
Procalcitonin-Guided Antibiotic Therapy in Bronchiectasis
To explore effectiveness of procalcitonin-guided antibiotic therapy in acute exacerbations of bronchiectasis, and to explore the clinical value of procalcitonin in bronchiectasis.
Completed
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year–80 year
Sex eligibility
Female
Study type
Interventional
Phase
Not applicable
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Bronchiectasis was diagnosed by high-resolution computed tomography based on the criteria published by McShane PJ et al.
- Acute exacerbations of bronchiectasis.
- Aged >= 18 years.
- Procalcitonin been detected after admission.
Exclusion criteria
- Associated with chronic obstructive pulmonary disease.
- Associated with asthma.
- Traction bronchiectasis caused by pulmonary fibrosis.
- Rule out other possible cause procalcitonin increased diseases such as cancer, connective tissue disease, active tuberculosis, chronic liver disease and respiratory system than the bacterial infection.
- Clinical data were incomplete.
- Can not follow up with the person.
Treatment and study plan
Clinical Experience
OtherThe application of antimicrobial agents is determined by clinical experience of doctors.
Primary outcomes
-
Antimicrobial prescription rate
Time frame: 14 days
-
Number of days of antimicrobial application
Time frame: 14 days
-
The number of days in hospital
Time frame: 14 days
Secondary outcomes
-
Effective rate of clinical treatment
Time frame: 14 days
-
Quality of life score
Time frame: 6 months
-
Adverse reaction rate
Time frame: 14 days
-
Bacterial resistance rate
Time frame: 14 days
-
The incidence of complications
Time frame: 14 days
-
fungal infection rate
Time frame: 14 days
-
mortality rate
Time frame: 14 days
-
The proportion of patients with at least once acute exacerbation in 6 months
Time frame: 6 months
Sponsors and collaborators
Lead sponsor
Qilu Hospital of Shandong University
Other
Registry information
Official study title
Effectiveness of Procalcitonin-Guided Antibiotic Therapy in Acute Exacerbations of Bronchiectasis: a Randomized Controlled Trial
Important dates
- Study start
- 2014
- Primary completion
- 2016
- Study completion
- 2017
- First posted
- Feb 23, 2017
- Registry last updated
- Feb 23, 2017
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Completed
Evaluation of the Clinical Relationship Between Procalcitonin Level and Bacteremia Agent in Intensive Care Unit Patients
NCT06958354
Bacteremia, Bacteremia and Sepsis
Ankara, Türkiye, Turkey (Türkiye)
View Trial Details
Completed
PCT Guided Stopping of Antibiotic Therapy in Children With Sepsis
NCT03388944
AMR, Antibiotic Use
Bengaluru, Karnataka, India
View Trial Details
Completed
Predictive Value of Procalcitonin for Bacteremia in the ICU
NCT03497741
Infections, Inflammation
Arnhem, Gelderland, Netherlands
View Trial Details
Completed
Establishment of an ELISA for the Recognition of Procalcitonin Variants in Patients With Hyperprocalcitonemia.
NCT05703802
Adiposity, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Münster, North Rhine-Westphalia, Germany
View Trial Details